Physician profile
Lorena Jauregui-Covarrubias
NPI 1861442741
$490,927.45
in general payments reported to CMS, 2019-2025
8 companies · $136K in 2025
The $136K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.20 · 2021: $42K · 2022: $92K · 2023: $94K · 2024: $127K · 2025: $136K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $356K · Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $356,310.08 |
| Food and Beverage | $257.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $356,310.08 | 2023-2025 | |
| Csl Behring | $134,260.00 | 2021-2022 | |
| Abbott Laboratories | $170.12 | 2024 | Freestyle Libre 3 |
| Abbvie INC. | $118.71 | 2021-2024 | |
| Lilly USA, LLC | $21.83 | 2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $19.32 | 2024 | |
| Novo Nordisk INC | $14.19 | 2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorena Jauregui-Covarrubias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.